Cite

HARVARD Citation

    van Rhee, F. et al. (2020). Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet. 7 (3), pp. e209-e217. [Online]. 
  
Back to record